277 unknown, 214 completed, 159 recruiting, 60 active not recruiting. 361 Phase 2, 158 Phase 3, 114 Phase 1, 98 Not applicable, 8 Early Phase 1.
Follow Nasopharyngeal Neoplasms: new trials by email Literature Review of Nasopharyngeal Neoplasms trials Research Report on Nasopharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 298 | 2026-12-01 | 2026-10-27 |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-12-01 | 2026-11-03 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-11 | 2026-11-06 |
| Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2026-11-01 | 2026-10-29 |
| Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features Assessment of EBV-related blood biomarkers and nasopharyngeal endoscopic scores - Nasopharyngeal Carcinoma (NPC) | Not yet recruiting | Zhongshan People's Hospital, Guangdong, China | 1500 | 2026-11-01 | 2026-11-05 | |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery Intraoperative soft palate suspension using the double-strap method., Intraoperative soft palate suspension using the full-wrap method. - Adenoid Hypertrophy, Tonsillar Hypertrophy | Not applicable | Not yet recruiting | Sun Yat-sen University | 138 | 2026-09-30 | 2026-07-10 |
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life Structured Swallowing Exercise, Conventional Swallowing Exercise - Nasopharyngeal Carcinoma (NPC) | Not applicable | Recruiting | Ira Mistivani, dr. Sp.KFR.N.M.(K). | 88 | 2026-09-09 | 2026-11-02 |
| A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma BL-B01D1, PD-1 monoclonal antibody, Gemcitabine - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 60 | 2026-09-01 | 2026-09-16 |
| Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma reduced dose group, Standard Dose Group, concurrent chemoradiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Fudan University | 269 | 2026-09-01 | 2026-08-27 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors BL-M08D1 - Nasopharyngeal Carcinoma (NPC), Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-09-01 | 2026-09-14 |
| A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-09-01 | 2026-09-15 |
| Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma Becotatug Vedotin - Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Kai Hu | 140 | 2026-09-01 | 2026-06-09 |
| Impacted Tooth Management and Osteoradionecrosis Risk in NPC Omission of Prophylactic Impacted Tooth Extraction, Prophylactic Impacted Tooth Extraction - Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw | Not applicable | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 536 | 2026-08-30 | 2026-08-14 |
| Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC), Myelosuppression | Recruiting | Nanfang Hospital, Southern Medical University | 1782 | 2026-08-26 | 2026-09-15 | |
| Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma Observation, Adjuvant therapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | Fudan University | 148 | 2026-08-01 | 2026-08-13 |
| Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | Hongmeng Yu | 25 | 2026-08-01 | 2026-08-24 |
| Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 48 | 2026-08-01 | 2026-07-16 |
Showing 20 of 825. Sign in to see all of them.
Nasopharyngeal Carcinoma (649) · Head and Neck Neoplasms (83) · Oropharyngeal Neoplasms (58) · Hypopharyngeal Neoplasms (56) · Laryngeal Neoplasms (55) · Mouth Neoplasms (53) · Squamous Cell Carcinoma of Head and Neck (44) · Carcinoma, Non-Small-Cell Lung (39) · Epstein-Barr Virus Infections (35) · Recurrence (34) · Neoplasm Metastasis (29) · Salivary Gland Neoplasms (29) · Stomach Neoplasms (29) · Lung Neoplasms (28)
Otorhinolaryngologic Neoplasms (824) · Pharyngeal Diseases (824) · Stomatognathic Diseases (824) · Neoplasms by Site (823) · Pharyngeal Neoplasms (823) · Otorhinolaryngologic Diseases (821) · Nasopharyngeal Diseases (820) · Neoplasms (806) · Head and Neck Neoplasms (742) · Neoplasms by Histologic Type (694) · Neoplasms, Glandular and Epithelial (689) · Carcinoma (669) · Respiratory Tract Diseases (91) · Respiratory Tract Neoplasms (90)
Cisplatin (161) · Gemcitabine (95) · Radiotherapy, Intensity-Modulated (73) · toripalimab (45) · Docetaxel (44) · Fluorouracil (43) · Capecitabine (42) · Radiotherapy (35) · camrelizumab (27) · Drug Therapy (24) · nimotuzumab (20) · pembrolizumab (19) · spartalizumab (18) · Carboplatin (15) · Paclitaxel (15)
Sun Yat-sen University (208) · Fudan University (27) · Zhejiang Cancer Hospital (24) · National Cancer Institute (NCI) (21) · Fujian Cancer Hospital (18) · Jiangxi Provincial Cancer Hospital (14) · National University Hospital, Singapore (13) · M.D. Anderson Cancer Center (11) · Ming-Yuan Chen (10) · Chinese University of Hong Kong (9) · Eye & ENT Hospital of Fudan University (9) · Nanfang Hospital, Southern Medical University (9) · National Cancer Centre, Singapore (9) · The University of Hong Kong (9) · Baylor College of Medicine (8)
China (516) · United States (128) · Singapore (40) · Taiwan (34) · Hong Kong (25) · Canada (24) · France (10) · Italy (10) · Malaysia (10) · Australia (9) · South Korea (8) · Thailand (8) · Spain (7) · United Kingdom (7) · Germany (5)
Jun Ma, M.D. (14) · Ming-Yuan Chen, MD,PhD (11) · Ming-Yuan Chen, MD, PhD (9) · Chaosu Hu, MD (6) · Jiade J Lu, MD (6) · Ming-yuan Chen, MD, PhD (5) · Yun-fei Xia, MD (5) · Chong Zhao, M.D (4) · Fang-Yun Xie, M.D. (4) · Jian Guan, Ph.D. (4) · Li Zhang, MD (4) · Wei Jiang, Ph.D. (4) · Xiaozhong Chen (4) · Xiaozhong Chen, MD (4) · A. Dimitrios Colevas, MD (3)
PMID 31150573, PMID 30207593, PMID 27686945, PMID 28837405, PMID 29584545, PMID 34341578, PMID 30213452, PMID 31178151, PMID 33492986, PMID 35240053, PMID 35997729, PMID 36746459, PMID 38507662, PMID 39970442, PMID 19564532, PMID 22154591, PMID 27567279, PMID 27567280, PMID 30620929, PMID 34111416, PMID 34174189, PMID 34990291, PMID 35355438, PMID 35709465, PMID 37207654, PMID 37409613, PMID 37537541, PMID 37580352, PMID 37801967, PMID 38520712, PMID 39438442, PMID 40890288, PMID 41791006, PMID 41813900, PMID 42580817, PMID 10640954, PMID 10811668, PMID 11212235, PMID 11224527, PMID 11375603, PMID 12646834, PMID 14710949, PMID 14871955, PMID 15033677, PMID 15172975, PMID 15542583, PMID 15735118, PMID 15746043, PMID 15752890, PMID 15920746
P30CA138292 (3), U10CA180868 (3), 2017 (2), 2019 (2), U10CA032102 (2), UM1CA186691 (2), 2014 (1), 2015 (1), 2018 (1), 2023 (1), 2025 (1), K01AT004415 (1), K24DC022077 (1), N01CM00099 (1), P01CA015396 (1)